Dermal Filler Documentation Template That Holds Up

The patient is happy. The cheeks look balanced. You have four minutes before the next room.

The note you write in those four minutes is the one that gets read if that patient calls at 9 pm about a purple patch on her nose.

Filler notes carry more weight than tox notes. The complications are worse. A good note shows what you put where, how you did it, what you checked, and what you were ready to do if something went wrong. Here is a template, a worked example, and the common gaps.

What should be in a defensible filler note?

A strong filler note contains core patient details, product traceability, precise placement, safety checks, emergency readiness, and immediate outcomes.

You need the same layers as any injectable note, plus three items specific to hyaluronic acid filler: the vascular safety check, the reversal agent on hand, and the plane of injection.

• Identifiers and authority: patient, injector, ordering provider, good faith exam date, consent date.

• Traceability: product, syringe lot, expiration, syringes opened, volume used and discarded.

• Placement: volume per area, plane and depth, entry points, needle or cannula gauge, technique.

• Safety steps: aspiration performed or not and why, aliquot size, capillary refill checked, blanching or disproportionate pain absent or present.

• Readiness: occlusion protocol on file, hyaluronidase available with lot and expiration.

• Outcome: pain control, immediate response, adverse events or none, aftercare, follow-up, photos.

Product labeling backs up the placement detail. The FDA directions for use for Juvederm Voluma XC indicate it for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation in adults over 21. They warn that intravascular injection may lead to embolization, occlusion, ischemia, or infarction. The label names immediate blanching and pain disproportionate to the procedure as warning signs. A note that records plane, volume, and the check for those signs tracks the label.

The fill-in template

• Patient name, DOB, chart ID:

• Date and time:

• Consent on file: signed filler consent dated ____ (verified today Y/N); occlusion and blindness risk discussed Y/N

• Good faith exam: performed by ____ (credential) on ____; no change since

• Patient-specific order dated ____ by ____

• Indication and areas treated:

• History reviewed today (prior filler, autoimmune or active infection, anticoagulants, recent dental work, herpes history):

• Product and manufacturer:

• Syringe lot(s): ____ Expiration: ____ Syringes opened: ____

• Volume per area (mL), each side separately:

• Plane and depth per area:

• Needle gauge ____ or cannula gauge and length ____; entry points:

• Technique per area (bolus, linear retrograde, fanning, microdroplet):

• Aspiration: performed Y/N at each bolus; result; if not, reason

• Injection pace: slow, aliquots of ____ mL or less

• Vascular assessment: capillary refill checked bilaterally Y/N; blanching none / present; pain proportionate Y/N; skin color and temperature at discharge

• Vascular occlusion protocol on file: name and version date ____

• Hyaluronidase available: product ____, lot ____, expiration ____, location ____

• Pain control (topical agent and time, ice, lidocaine in product, block):

• Immediate response and adverse events (or "none observed"):

• Total volume used ____ mL; discarded ____ mL

• Aftercare given (verbal and written), including after-hours number

• Follow-up plan:

• Photos: pre and post taken Y/N; if declined, note it

• Injector name, credentials, signature, time; supervising physician, NP, or PA:

A worked example

Here is how a completed note looks in practice. Everything below is fictional, including the patient, the lots, and the staff.

• Patient: D. Marchetti, DOB 08/30/1979, chart 20917

• Date and time: 09/17/2026, 10:30 am

• Consent on file: signed filler consent dated 09/17/2026; occlusion, necrosis, and vision loss risks discussed

• Good faith exam: performed by S. Patel, NP, on 09/03/2026 (in person); no change since

• Patient-specific order dated 09/03/2026 by S. Patel, NP: HA filler to midface, up to 2 mL

• Indication: midface volume loss, bilateral cheeks; no prior filler, no anticoagulants, no active infection

• Product: Juvederm Voluma XC, Allergan Aesthetics (AbbVie)

• Syringe lot numbers: VX88213K and VX88213L (fictional); expiration 05/2027; 2 syringes opened

• Volume per area: right cheek 1.0 mL (arch 0.4, anteromedial cheek 0.6); left cheek 1.0 mL (arch 0.4, anteromedial cheek 0.6)

• Plane: supraperiosteal boluses at the arch; deep subcutaneous with cannula at the anteromedial cheek

• Delivery: 27g 0.5 inch needle for arch boluses; 25g 50 mm cannula, one entry point per side, for anteromedial cheek

• Technique: bolus at arch; retrograde fanning with cannula

• Aspiration: before each needle bolus, held 5 seconds, negative at all sites; not performed with cannula

• Injection pace: slow, aliquots 0.1 mL or less

• Vascular assessment: capillary refill under 2 seconds bilaterally after each area and at discharge; no blanching; pain proportionate; skin warm and pink

• Vascular occlusion protocol on file: version 06/2026, approved by A. Chen, MD

• Hyaluronidase available: Hylenex recombinant 150 USP units per mL, 1 mL vial x 4, lot HY5521 (fictional), expiration 03/2027, treatment room refrigerator

• Pain control: topical 4% lidocaine 20 minutes, ice; product contains lidocaine

• Immediate response: mild edema, no ecchymosis; adverse events: none observed

• Total volume used 2.0 mL; discarded 0 mL

• Aftercare: no pressure or massage for 24 hours, call the after-hours line for increasing pain, color change, or vision change; written sheet given with number

• Follow-up: 2 week check scheduled

• Photos: pre and post taken, frontal and bilateral oblique

• Injector: M. Okafor, RN, signed 11:05 am; supervising physician A. Chen, MD

The technique above is one reasonable approach, not a rigid rule.

The CMAC guideline on hyaluronic acid filler vascular occlusion, published in the Journal of Clinical and Aesthetic Dermatology, recommends cannulas of 25 gauge or larger, slow injection in small volumes, and knowledge of high-risk zones. It also states that a negative aspirate does not mean the injection will be safe, citing reliability of 33 to 63%. Your medical director sets your protocol. Chart it.

What are the most common mistakes in filler documentation?

The biggest charting mistakes are writing vague locations, leaving out vascular checks, skipping emergency details, and omitting discarded volume.

Here is what goes wrong most often:

• "Filler to cheeks, 2 mL, tolerated well." This tells us nothing. No lot, no plane, no per-side volume, no gauge.

• No record of a vascular check. Writing "no complications" is a conclusion, not data. Refill checked, no blanching, and proportionate pain is real evidence.

• No reference to the protocol or the reversal agent. Your note should show you were prepared before anything went wrong.

• Aftercare without the after-hours number. Late occlusions are often caught by a phone call.

• Volume discarded not recorded. Audits and product recalls both require this.

How does Symbal help with filler notes?

Symbal lets injectors narrate the visit out loud, then formats the clinical details into structured fields.

We built Symbal so you can speak your way through the appointment. Symbal records, transcribes, and writes a structured note. It puts product, lot, volume per area, plane, and the vascular check on their own lines.

You review and approve the draft. Then our Chrome extension fills the fields in Boulevard, Aesthetic Record, or PatientNow. If you use Aesthetic Record on an iPad, you copy and paste from the Symbal app.

Frequently asked questions

What do I document if I suspect an occlusion?

Document the exact time of the first sign, what you saw, when you stopped, and every action you took with a timestamp.

Record blanching, livedo patterns, delayed refill, or pain out of proportion. Note when you stopped injecting. Then log every step after that with a clear clock time: massage, heat, hyaluronidase product name, lot, units, sites, and each repeat dose. The CMAC guideline describes stopping at once, checking refill on both sides, applying massage and heat, and giving prompt hyaluronidase with possible redosing at one hour. Record who you called and the discharge or transfer plan.

Do I need to chart hyaluronidase on hand every visit?

You should chart hyaluronidase on hand because it shows you were ready to treat an occlusion before you injected.

Nothing we found explicitly requires it in every note. But it costs one line and answers the first question asked after a complication. Hylenex recombinant is labeled at 150 USP units per mL and stored refrigerated, so lot and expiration change over time. Verify with a healthcare attorney or your medical director to be sure.

How detailed should technique be?

Technique should be detailed enough that another qualified injector could recreate your approach.

Include gauge, length, entry point, plane, technique name, aliquot size, and per-area volume. Writing "cannula technique" alone is not enough.

Your best filler note is written before you need it. Try Symbal free for 7 days, no credit card required.